UNSPSC 51101682: Satranidazole

This classification denotes an antiprotozoal agent with the molecular formula C8H11N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4N7G8A6439, chemically known as 2-imidazolidinone, 1-(1-methyl-5-nitro-1h-imidazol-2-yl)-3-(methylsulfonyl)- but generally known as satranidazole, which bears US NIH Compound Identifier 41841. European Medicines Agency schedules Satranidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10459MIG.

UNSPSC 51101682 Satranidazole, a Commodity code, nominally covers a single antiprotozoal pharmaceutical ingredient, but recent state and local opportunities tagged under this code show little activity actually purchasing satranidazole itself. Instead, the tagged solicitations involve broader pharmaceutical procurement — antibiotic tablets, naloxone, and drug deactivation systems — suggesting either tagging drift or that satranidazole procurement bundles with general pharmaceutical supply. State and local health departments and county health authorities appear to be the primary issuing bodies, sourcing pharmaceutical products through both piggyback cooperative purchasing agreements (such as the MMCAP Infuse consortium) and traditional competitive bidding for emergency medical and public health supplies. Work includes warehouse pharmaceutical supply agreements with multi-year terms and renewal options, as well as community health initiatives requiring quarterly or regular deliveries to specified health facilities.

Recent activity centers on Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 through the MMCAP Infuse consortium for antibiotic tablets (Solicitation 26482DPHPREPDB53392), while Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (Solicitation IFB60459723LAS, response due July 26, 2023). The mismatch between the code's nominal scope and the actual products in recent opportunities suggests this code may not be the primary pathway for satranidazole procurement in state and local markets, or that current buying activity under this tag reflects procurement system inconsistencies rather than genuine demand for the ingredient itself.